Adaptin Bio is launching with plans to bring a bispecific T cell engager for glioblastoma, a deadly form of brain cancer, into the clinic.
The company received FDA clearance to start its clinical trial, which will be run at Duke University and enroll around 25 patients. The bispecific T cell engager was developed by researchers led by John Sampson, who previously was chair of the neurosurgery department at Duke and is now dean of the University of Colorado’s School of Medicine.
Duke’s work on the therapy was supported by a $5 million NIH grant, and Adaptin conducted preclinical work on the asset with funds from an undisclosed pre-seed round. Adaptin is closing its seed round this week, but declined to disclose the amount. The company is led by Michael Roberts, who previously was VP of business development at Chelsea Therapeutics, which Lundbeck acquired in 2014.
The drug, called APTN-101, is…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
